Tags

Type your tag names separated by a space and hit enter

Adiponectin and renal function, and implication as a risk of cardiovascular disease.
Am J Cardiol. 2006 Dec 15; 98(12):1603-8.AJ

Abstract

The relation among adiponectin, renal function, and incident cardiovascular disease (CVD) in patients with different degrees of renal dysfunction was investigated. In total, 150 subjects were included in this study and followed prospectively for a mean of 32 months. At baseline, median adiponectin levels for chronic kidney disease (CKD) stages 1, 2, 3, 4 and 5, as estimated by creatinine clearance (> or =90, 60 to 90, 30 to 60, <30 ml/min), were 3.06, 4.04, 6.43, and 11.9 microg/ml, respectively (p for trend <0.01), and a significant association between adiponectin and CKD stages was also confirmed in multivariate regression analysis (F = 6.2, p <0.001). During follow-up, 31 subjects developed CVD, including myocardial infarction, angina pectoris, stroke, and transient ischemic attack. Gender-specific median values of adiponectin were used to separate the higher group from the lower group, and the Kaplan-Meier curve showed a significantly lower event-free survival rate in the lower adiponectin group (<4.39 microg/ml in men, <6.84 microg/ml in women, chi-square 4.88, p <0.03). The risk factor-adjusted Cox regression showed that an increase in adiponectin per 1 microg/ml was associated with a decrease in the risk of CVD to 0.86 (95% confidence interval 0.75 to 0.96, p = 0.004). In the subgroup with previous ischemic heart disease (IHD; n = 65), a significantly lower event-free survival rate of IHD was also observed in the lower adiponectin group (<4.45 microg/ml in men, <4.49 microg/ml in women, chi-square 3.96, p <0.05). The relative distribution of adiponectin isoforms was examined in patients with severe CKD, and the percentage of the high-molecular-weight form in patients with IHD during follow-up (n = 3) was significantly smaller than that in those without IHD (n = 4, p <0.02). In conclusion, renal function is a significant regulator of adiponectin when categorized by CKD stage, whereas hypoadiponectinemia is a predictor of CVD, including recurrent IHD.

Authors+Show Affiliations

Department of Geriatric Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

17145218

Citation

Iwashima, Yoshio, et al. "Adiponectin and Renal Function, and Implication as a Risk of Cardiovascular Disease." The American Journal of Cardiology, vol. 98, no. 12, 2006, pp. 1603-8.
Iwashima Y, Horio T, Kumada M, et al. Adiponectin and renal function, and implication as a risk of cardiovascular disease. Am J Cardiol. 2006;98(12):1603-8.
Iwashima, Y., Horio, T., Kumada, M., Suzuki, Y., Kihara, S., Rakugi, H., Kawano, Y., Funahashi, T., & Ogihara, T. (2006). Adiponectin and renal function, and implication as a risk of cardiovascular disease. The American Journal of Cardiology, 98(12), 1603-8.
Iwashima Y, et al. Adiponectin and Renal Function, and Implication as a Risk of Cardiovascular Disease. Am J Cardiol. 2006 Dec 15;98(12):1603-8. PubMed PMID: 17145218.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Adiponectin and renal function, and implication as a risk of cardiovascular disease. AU - Iwashima,Yoshio, AU - Horio,Takeshi, AU - Kumada,Masahiro, AU - Suzuki,Yoshihiko, AU - Kihara,Shinji, AU - Rakugi,Hiromi, AU - Kawano,Yuhei, AU - Funahashi,Tohru, AU - Ogihara,Toshio, Y1 - 2006/10/18/ PY - 2006/03/29/received PY - 2006/07/03/revised PY - 2006/07/03/accepted PY - 2006/12/6/pubmed PY - 2007/1/31/medline PY - 2006/12/6/entrez SP - 1603 EP - 8 JF - The American journal of cardiology JO - Am. J. Cardiol. VL - 98 IS - 12 N2 - The relation among adiponectin, renal function, and incident cardiovascular disease (CVD) in patients with different degrees of renal dysfunction was investigated. In total, 150 subjects were included in this study and followed prospectively for a mean of 32 months. At baseline, median adiponectin levels for chronic kidney disease (CKD) stages 1, 2, 3, 4 and 5, as estimated by creatinine clearance (> or =90, 60 to 90, 30 to 60, <30 ml/min), were 3.06, 4.04, 6.43, and 11.9 microg/ml, respectively (p for trend <0.01), and a significant association between adiponectin and CKD stages was also confirmed in multivariate regression analysis (F = 6.2, p <0.001). During follow-up, 31 subjects developed CVD, including myocardial infarction, angina pectoris, stroke, and transient ischemic attack. Gender-specific median values of adiponectin were used to separate the higher group from the lower group, and the Kaplan-Meier curve showed a significantly lower event-free survival rate in the lower adiponectin group (<4.39 microg/ml in men, <6.84 microg/ml in women, chi-square 4.88, p <0.03). The risk factor-adjusted Cox regression showed that an increase in adiponectin per 1 microg/ml was associated with a decrease in the risk of CVD to 0.86 (95% confidence interval 0.75 to 0.96, p = 0.004). In the subgroup with previous ischemic heart disease (IHD; n = 65), a significantly lower event-free survival rate of IHD was also observed in the lower adiponectin group (<4.45 microg/ml in men, <4.49 microg/ml in women, chi-square 3.96, p <0.05). The relative distribution of adiponectin isoforms was examined in patients with severe CKD, and the percentage of the high-molecular-weight form in patients with IHD during follow-up (n = 3) was significantly smaller than that in those without IHD (n = 4, p <0.02). In conclusion, renal function is a significant regulator of adiponectin when categorized by CKD stage, whereas hypoadiponectinemia is a predictor of CVD, including recurrent IHD. SN - 0002-9149 UR - https://www.unboundmedicine.com/medline/citation/17145218/Adiponectin_and_renal_function_and_implication_as_a_risk_of_cardiovascular_disease_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0002-9149(06)01715-2 DB - PRIME DP - Unbound Medicine ER -